Advertisement

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers

  • Nathaniel Melling
  • Kai Bachmann
  • Bianca Hofmann
  • Alexander Tarek El Gammal
  • Matthias Reeh
  • Oliver Mann
  • Christoph Moebius
  • Marco Blessmann
  • Jakob Robert Izbicki
  • Katharina GruppEmail author
Original Article – Cancer Research

Abstract

Introduction

Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.

Materials and methods

This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens.

Results

While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225).

Conclusions

In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.

Keywords

RBM3 Lung adenocarcinoma Squamous cell lung carcinoma Large cell lung carcinoma Non-small-cell lung carcinoma Immunohistochemistry 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Al-Fageeh MB et al (2009) Cold-inducible RNA binding protein (CIRP) expression is modulated by alternative mRNAs. RNA (New York, N.Y.) 15:1164–1176CrossRefGoogle Scholar
  2. Boman K et al (2013) Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol 13:17CrossRefGoogle Scholar
  3. Derry JMJ et al (1995) RBM3 a novel human gene in Xp11.23 with a putative RNA-binding domain. Hum Mol Genet 4:2307–2311CrossRefGoogle Scholar
  4. Ehlén A et al (2010) Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Trans Med 8:78CrossRefGoogle Scholar
  5. Ehlén Õ et al (2011) RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol 4:212CrossRefGoogle Scholar
  6. Grupp K et al (2014) High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. Eur J Cancer (Oxford, England: 1990) 50:852–861CrossRefGoogle Scholar
  7. Hjelm B et al (2011) High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteom Clin Appl 5:624–635CrossRefGoogle Scholar
  8. Jögi A et al (2009) Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Modern Pathol 22:1564–1574CrossRefGoogle Scholar
  9. Jonsson L et al (2011a) High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagn Pathol 6:91CrossRefGoogle Scholar
  10. Jonsson L et al (2011b) Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study. J Trans Med 9:114CrossRefGoogle Scholar
  11. Jonsson L et al (2014) High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomarker Res 2:11CrossRefGoogle Scholar
  12. Kita H (2002) Modulation of polyglutamine-induced cell death by genes identified by expression profiling. Hum Mol Genet 11:2279–2287CrossRefGoogle Scholar
  13. Lleonart ME (2010) A new generation of proto-oncogenes: cold-inducible RNA binding proteins. Biochimica et biophysica acta 1805:43–52Google Scholar
  14. Martínez-Arribas F et al (2006) Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer. J Cell Biochem 97:1275–1282CrossRefGoogle Scholar
  15. Melling N et al (2016) Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer. Histopathology 68:191–198CrossRefGoogle Scholar
  16. Mirlacher M et al (2010) Recipient block TMA technique. Methods Mol Biol (Clifton NJ) 664:37–44CrossRefGoogle Scholar
  17. Nodin B et al (2012) High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma. Diagn Pathol 7:82CrossRefGoogle Scholar
  18. Olofsson S-E et al (2015) Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer. PloS one 10:e0121300CrossRefGoogle Scholar
  19. Sureban SM et al (2008) Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene 27:4544–4556CrossRefGoogle Scholar
  20. Wellmann S et al (2004) Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci 117:1785–1794CrossRefGoogle Scholar
  21. Wellmann S et al (2010) The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res 67:35–41CrossRefGoogle Scholar
  22. Wright CF et al (2001) Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins. J Biol Chem 276:40680–40686CrossRefGoogle Scholar
  23. Wurth L, Gebauer F (2014) RNA-binding proteins, multifaceted translational regulators in cancer. Biochim Biophys Acta 1849(7):881–886.  https://doi.org/10.1016/j.bbagrm.2014.10.001 CrossRefGoogle Scholar
  24. Zeng Y et al (2009) Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem 107:179–188CrossRefGoogle Scholar
  25. Zhang H-T et al (2013) Differential expression of the RNA-binding motif protein 3 in human astrocytoma. Chin Med J 126:1948–1952Google Scholar
  26. Zhou R-B et al (2017) RNA binding motif protein 3: A potential biomarker in cancer and therapeutic target in neuroprotection. Oncotarget 8:22235–22250Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Nathaniel Melling
    • 1
  • Kai Bachmann
    • 1
  • Bianca Hofmann
    • 1
  • Alexander Tarek El Gammal
    • 1
  • Matthias Reeh
    • 1
  • Oliver Mann
    • 1
  • Christoph Moebius
    • 2
  • Marco Blessmann
    • 2
  • Jakob Robert Izbicki
    • 1
  • Katharina Grupp
    • 1
    • 2
    Email author
  1. 1.General-, Visceral and Thoracic Surgery Department and ClinicUniversity Medical Center Hamburg-EppendorfHamburgGermany
  2. 2.Department of Plastic-, Reconstructive and Aesthetic SurgeryUniversity Medical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations